Radical resection, Masaoka–Koga stage predict survival in thymic neuroendocrine tumors

Posted on July 19, 2022

Patients with thymic neuroendocrine tumors, a heterogeneous group of rare diseases, require systemic therapy and integrated management. A recent study found that radical resection and Masaoka–Koga stage were independent prognostic factors for the survival of these patients.

The study analyzed data from 104 patients diagnosed with thymic neuroendocrine tumors, of which 13.46% had multiple endocrine neoplasia and 26.92% had ectopic adrenocorticotropic hormone syndrome.

Most patients (93.27%) underwent surgical resection, with most of those (81.44%) having radical resection. Five patients were lost during follow-up. The 1-, 3- and 5-year overall survival rates were 91.8%, 70.2%, and 54.6%, respectively, with a median overall survival of 61.57 months.

Amongst the 99 patients followed for the study period, age at diagnosis, radical resection, pathological grade, and Masaoka–Koga stage had made significant differences in overall survival.

Amongst those who underwent surgery, age at diagnosis, neoadjuvant therapy, radical resection, pathological grade, and Masaoka–Koga stage led to a significant difference in overall survival.

Chen Y, Zhang J, Zhou M, et al. Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysis. Orphanet J Rare Dis. 2022;https://doi.org/10.1186/s13023-022-02366-x